FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387639200> ?p ?o ?g. }

• W4387639200 abstract "The use of bortezomib which is a proteasome inhibitor has been demonstrated to be efficacious in small number of patients as a desensitization strategy in heart transplant. We reviewed our single center's experience using Bortezomib along with plasmapheresis as desensitization therapy for highly sensitized patients to assess pre- and post-transplant outcomes.We assessed 43 highly sensitized patients awaiting HTx (defined as cPRA > 50%) between 2010 and 2021 who underwent desensitization therapy with bortezomib. Only those patients who subsequently underwent HTx were included in this study. Enrolled patients received up to four doses of bortezomib (1.3 mg/m2 ) over 2 weeks in conjunction with plasmapheresis. The efficacy of PP/BTZ was assessed by comparing the calculated panel reactive antibodies to HLA class I or class II antigens. Post-transplant outcomes including overall survival and incidence of rejection were compared to those of non-sensitized patients (PRA < 10%, n = 649) from the same center.The average cPRA prior to PP/BTZ was 94.5%. Post-PP/BTZ there was no statistically significant decline in mean cPRA, class I cPRA, or class II cPRA, though the average percentage decrease in class I cPRA (8.7 ± 17.0%) was higher than the change in class II cPRA (4.4 ± 13.3%). Resulted were also replicated with C1q-binding antibodies showing more effect on I class compared to class II (15.0 ± 37.4% vs. 6.8 ± 33.6%) as well as with 1:8 dilutional assay (14.0 ± 23.0% vs. 9.1 ± 34.9%). Additionally, PP/BTZ treated patients and the control group of non-sensitized patients had similar overall 1 year survival (95.4 vs. 92.5%) but patients with PP/BTZ had increased incidence of AMR (79.1% vs. 97.1%, p = < .001), any treated rejection (62.8% vs. 86.7%, p = < .001) and de novo DSA development (81.4% vs. 92.5%, p = .007). Major side effects of PP/BTZ included thrombocytopenia (42%), infection requiring antibiotics (28%), and neuropathy (12%).The use of bortezomib in highly sensitized patients does not significantly lower circulating antibodies prior to heart transplantation. However, its use may improve the chances of obtaining an immuno-compatible donor heart and contribute to acceptable post-transplant outcomes." @default.
• W4387639200 created "2023-10-15" @default.
• W4387639200 creator A5001620639 @default.
• W4387639200 creator A5008256464 @default.
• W4387639200 creator A5011986787 @default.
• W4387639200 creator A5015462321 @default.
• W4387639200 creator A5017421550 @default.
• W4387639200 creator A5019163314 @default.
• W4387639200 creator A5020489903 @default.
• W4387639200 creator A5020746104 @default.
• W4387639200 creator A5025486781 @default.
• W4387639200 creator A5034147901 @default.
• W4387639200 creator A5052345783 @default.
• W4387639200 creator A5065002546 @default.
• W4387639200 creator A5083295306 @default.
• W4387639200 creator A5087709436 @default.
• W4387639200 creator A5091270315 @default.
• W4387639200 date "2023-10-14" @default.
• W4387639200 modified "2023-10-16" @default.
• W4387639200 title "Does bortezomib influence pre‐transplant desensitization therapy or benefit post‐heart transplant outcomes for highly sensitized patients?" @default.
• W4387639200 cites W1506151781 @default.
• W4387639200 cites W1506252195 @default.
• W4387639200 cites W1815626776 @default.
• W4387639200 cites W2000381123 @default.
• W4387639200 cites W2018618115 @default.
• W4387639200 cites W2044005280 @default.
• W4387639200 cites W2050846843 @default.
• W4387639200 cites W2056360451 @default.
• W4387639200 cites W2105395887 @default.
• W4387639200 cites W2169183166 @default.
• W4387639200 cites W2171906067 @default.
• W4387639200 cites W2328401697 @default.
• W4387639200 cites W2331825840 @default.
• W4387639200 cites W2554191614 @default.
• W4387639200 cites W2587841779 @default.
• W4387639200 cites W2792011991 @default.
• W4387639200 cites W2899465875 @default.
• W4387639200 cites W3106626862 @default.
• W4387639200 cites W3135564612 @default.
• W4387639200 cites W4317535362 @default.
• W4387639200 cites W53279463 @default.
• W4387639200 doi "https://doi.org/10.1111/ctr.15165" @default.
• W4387639200 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37837612" @default.
• W4387639200 hasPublicationYear "2023" @default.
• W4387639200 type Work @default.
• W4387639200 citedByCount "0" @default.
• W4387639200 crossrefType "journal-article" @default.
• W4387639200 hasAuthorship W4387639200A5001620639 @default.
• W4387639200 hasAuthorship W4387639200A5008256464 @default.
• W4387639200 hasAuthorship W4387639200A5011986787 @default.
• W4387639200 hasAuthorship W4387639200A5015462321 @default.
• W4387639200 hasAuthorship W4387639200A5017421550 @default.
• W4387639200 hasAuthorship W4387639200A5019163314 @default.
• W4387639200 hasAuthorship W4387639200A5020489903 @default.
• W4387639200 hasAuthorship W4387639200A5020746104 @default.
• W4387639200 hasAuthorship W4387639200A5025486781 @default.
• W4387639200 hasAuthorship W4387639200A5034147901 @default.
• W4387639200 hasAuthorship W4387639200A5052345783 @default.
• W4387639200 hasAuthorship W4387639200A5065002546 @default.
• W4387639200 hasAuthorship W4387639200A5083295306 @default.
• W4387639200 hasAuthorship W4387639200A5087709436 @default.
• W4387639200 hasAuthorship W4387639200A5091270315 @default.
• W4387639200 hasConcept C126322002 @default.
• W4387639200 hasConcept C141071460 @default.
• W4387639200 hasConcept C159654299 @default.
• W4387639200 hasConcept C170493617 @default.
• W4387639200 hasConcept C203014093 @default.
• W4387639200 hasConcept C2776364478 @default.
• W4387639200 hasConcept C2777478702 @default.
• W4387639200 hasConcept C2778842783 @default.
• W4387639200 hasConcept C2778849806 @default.
• W4387639200 hasConcept C2779779143 @default.
• W4387639200 hasConcept C2911091166 @default.
• W4387639200 hasConcept C71924100 @default.
• W4387639200 hasConcept C90924648 @default.
• W4387639200 hasConceptScore W4387639200C126322002 @default.
• W4387639200 hasConceptScore W4387639200C141071460 @default.
• W4387639200 hasConceptScore W4387639200C159654299 @default.
• W4387639200 hasConceptScore W4387639200C170493617 @default.
• W4387639200 hasConceptScore W4387639200C203014093 @default.
• W4387639200 hasConceptScore W4387639200C2776364478 @default.
• W4387639200 hasConceptScore W4387639200C2777478702 @default.
• W4387639200 hasConceptScore W4387639200C2778842783 @default.
• W4387639200 hasConceptScore W4387639200C2778849806 @default.
• W4387639200 hasConceptScore W4387639200C2779779143 @default.
• W4387639200 hasConceptScore W4387639200C2911091166 @default.
• W4387639200 hasConceptScore W4387639200C71924100 @default.
• W4387639200 hasConceptScore W4387639200C90924648 @default.
• W4387639200 hasLocation W43876392001 @default.
• W4387639200 hasLocation W43876392002 @default.
• W4387639200 hasOpenAccess W4387639200 @default.
• W4387639200 hasPrimaryLocation W43876392001 @default.
• W4387639200 hasRelatedWork W131145346 @default.
• W4387639200 hasRelatedWork W2034277983 @default.
• W4387639200 hasRelatedWork W2044068118 @default.
• W4387639200 hasRelatedWork W2409648752 @default.
• W4387639200 hasRelatedWork W2413251061 @default.
• W4387639200 hasRelatedWork W2419129340 @default.
• W4387639200 hasRelatedWork W2463745230 @default.
• W4387639200 hasRelatedWork W2465180411 @default.

• next